CEO's are having a tough time getting employees back to work

18 months into the pandemic, if we thought that staffing shortage and workers issues were limited to laborers then we couldn't have been more wrong. CEOs of many large-scale enterprises are running out of options to get their employees to come back to work. They've tried offering higher pay, flexible work hours, pensions, tuition coverage, phased retirement model, hybrid work scheduled, and much more, yet they are unable to lure the employees to come back to work.  CNBC sources David Faber and Jim Cramer said that they personally know CEO of multinational companies who are "out of their wits" trying to get employees. 

Cramer believes that a possible solution might be the approval of a COVID drug by Merck and Ridgeback Biotherapeutics, it will be reassuring for people who are worried about getting sick at work. Merck and Ridgeback have developed an oral treatment for COVID and they are going to seek emergency authorization in the US for the same. The drug named Molnupiravir reduced the risk of hospitalization or death by 50% among patients with mild covid cases. If cleared, this drug will is the first oral antiviral for COVID. This becomes even more dire as the spike in cases continues due to the Delta Variant. 

Source: CNBC